UCB (EBR:UCB) UCB Media Room: Acquisition of own shares

Transparency directive : regulatory news

26/04/2024 20:00

https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC= rjYrJUHPDVbu1NKaBE-3DhKKA_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2= FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN= n-2B6FohpNoV333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWR= QywHmnf3RHbTe2B7FTHwvZmqOIosUflhU1XHDpap0x1oV1KsBHQ91mmOxCUxjevl6Pxp4g3U4wO= eVP2nt8DDkTdVt-2Fh5IUfU8XWbvWZI6QfVxS71B2y4Oh9P-2FgQW8aG6oAv6WY-2FFGUeUWpbG= JrJyJVKpObpaOfltahdyYcFe0IZzcFqg-3D ** Acquisition of own shares ------------------------------------------------------------ Brussels (Belgium), 26 April 2024 =E2=80=93 20:00 (CEST) =E2=80=93 Regulate= d information=C2=A0 In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB= =E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose= s certain information in relation to its Share Repurchase Program 2024.=C2= =A0 Under this program, UCB has requested a financial intermediary to repurchas= e up to 1,300,000 UCB shares on its behalf under the terms of a discretiona= ry mandate agreement with initial validity until 30 June 2024, effective as= from 02 April 2024, to cover current and future obligations under UCB's Lo= ng Term Incentive Plans for its personnel. In the framework of this Share Repurchase Program 2024, UCB repurchased 15.= 994 UCB shares on Euronext Brussels in the period from 19 April 2024 up to = and including 26 April 2024. No purchase of own shares was made in the peri= od from 22 April up to and including 26 April 2024, in the framework of the= organization of UCB=E2=80=99s Annual General Meeting. https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepZDUN4KZf5FcFfoSVl2v2mQY-2BAp6qtKdwUd4iRvMKOx1lpU1XX= uaIQ0cC40rMNm572WyEmxIVrN21eapAEKwDOfggwH_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFG= M-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8= cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1KlmycSfC-2= FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOIuWKsNUH4YjZ-2B5vrXnIr7MjG1YWX3ntC= tG7he-2B4WEIxZZFSJrcpKYzLcNyqV2tMzKxYLN7LmWjaSGEvxLj2ePEGyga-2Fvjuv3UGlDx25= T3pQ-2BRBYJDZKFAe9UNuIW3rDEjPt13cl5VtvCvMKiBidILao-3D This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUz= lo7XKIuSly0rC4Oa12rFuiaXNgb0F6L7ybSCidGRlUFwTxzrkzCt6dOMzdZPcjqPbg8jratFLJj= fTg-3D-3DLt3D_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BI= fez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV= 333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbT= e2B7FTHwvZmqOIo6MlsdQ71TPAIgYWZsQCYMRM2MlboFrq-2BT-2F6vN2gCWmS2g2m0rvf6yxas= mlJ4-2B2I6kv4U4UBNkmHVffRLJzLoHP6Wgo14rv2fRlwZtuU-2Fpv2aUX1jlkXPQ9kneqEPO-2= FB9pe2N-2FiVRk63p2jGxsra4E-3D . For further information, contact UCB:=C2=A0 Investor Relations Antje Witte=C2=A0 T +32 2 559 94 14 Antje.Witte@ucb.com Corporate Communications Laurent Schots=C2=A0 T+32 2 559 92 64 laurent.schots@ucb.com =C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 9,000 peopl= e in approximately 40 countries, the company generated revenue of =E2=82=AC= 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll= ow us on Twitter: @UCB_news. =C2=A0 GenericFile 240426 - Acquisition of own shares ENG (https://u7061146.ct.sendgrid.net/ls= /click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZDUN4KZf5Fc= FfoSVl2v2mQIwK7Mvsc9w4E1VsHHXKgsC20tQaPQHwiiWmMSxYJZpc-3DhsZ8_2dCLUNbuBjhX7= 46-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd= 4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z7879AXAcg1Lof= BiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOIpT5APS-2BUNUX= IIhCuV3CUJ3EbdVhW8UJcRFG0AIYxOyNXIkJeRoMWEwkSXlUTMTkAGxVUSFMHFYCOQk7mP4G4xL= -2Fy2zbTFdD7pkI2df-2FQurR5npKPW9hZX7-2Bd6WfSp14gnFCwv76ArJ-2F39ro2XzFjWo-3D= GenericFile 240426 - Verwerving van eigen aandelen NL (https://u7061146.ct.sendgrid.net= /ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZDUN4KZf= 5FcFfoSVl2v2mQ-2BhH4HTmK769LGY-2BT3E-2FATZ-2BmfD2RLURTxOqKPJ7u-2B5c-3DjtL9_= 2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mp= lcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z= 7879AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOI= m-2FlN-2B94p4MC5glah83X9f64UnkIa8uajHJN4WZqDoyR0aezzMW63rj0Icgu4-2FdN7WhtWz= 6MxFEpJLBDn8ZSbNdaPE6pSCRmGBG3E1W-2BTm5cqs5CmgCo38IArKNzPXfDLe6CbeJ9EfIQngN= 0GdKzggQ-3D GenericFile 240426 - Acquisition actions propres FR Draft 002 (https://u7061146.ct.send= grid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHep= ZDUN4KZf5FcFfoSVl2v2mQcG22YYwqkjwVi5A7t8RYsfakrpSypH2zYJHTIUYKdnI-3DKPIV_2d= CLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplc= EW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z78= 79AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOIu2= x-2BeyWG1xXmAq10QbvhroGuwdr1aiTgNhnpD96SUHvyotRQXwN6BW3UsrBir2-2B6cXPROqhqY= 9a3wxTxF1dxVQsUpHK0pGxKDeuhfxBaC2H5znk4EYhbA5eTdnbZAQB1p8XwhRJNyeEopwNTFnlD= yM-3D Image Chart 1 April 26 2024 ENG (https://u7061146.ct.sendgrid.net/ls/click?upn=3D= u001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZDUN4KZf5FcFfoSVl2v2mQY-= 2BAp6qtKdwUd4iRvMKOx1tT1gDxlp2mFnyXT1HNMwgw-3DV44j_2dCLUNbuBjhX746-2FvM63L9= Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO= 93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1K= lmycSfC-2FYVaxRY8jPqKnPWRQywHmnf3RHbTe2B7FTHwvZmqOIvCntXbT0e0-2Bry8boQIQecP= DTzqbq7GtoNBLJU9YH1rD-2BWxYcKSXVW7kMlCb3IUQUnaVn0dW2ltFpwdIsrAqAxbHckWePGNT= Ed8OMebRZnS6o0ouPhYRmnK982q5xLEDdDje30oheGhAmh873EdTh5I-3D ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu= Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNlOYgMRxA6-2BpVOoZl6QBhbJ= ERDGVuWFaxpPa7x3pIiRoTWw9NPQ7ypmmdjQJ7HuOtGXjnD4Jn9iVs5YMktmCY9begWkqkiXt-2= FxF5uZ8JKwNQ-3DOItG_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2= nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6F= ohpNoV333ZtNhorLky6z7879AXAcg1LofBiyvC5j2J1KlmycSfC-2FYVaxRY8jPqKnPWRQywHmn= f3RHbTe2B7FTHwvZmqOIuPb1TVn3fQC3arm2tby-2FhMtTJSG8v2I5DQ61dafOCUETnTKd-2FnX= 4ZcBUv4gD8EUW688xynBdtYN3UwlGxfrEA0SPa5DgATqQV5kwTtZuA4ye1CXgAclro0oEaUMx2a= QjcgZiE-2B3DhHZoQSMjAnlNHA-3D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium

source : webdisclosure.com

UCB's latest news

26/04/2024 20:00

UCB (EBR:UCB) UCB Media Room: Acquisition of own shares

Transparency directive : regulatory news

UCB's latest news

Other stories